818 related articles for article (PubMed ID: 21779496)
1. Raf family kinases: old dogs have learned new tricks.
Matallanas D; Birtwistle M; Romano D; Zebisch A; Rauch J; von Kriegsheim A; Kolch W
Genes Cancer; 2011 Mar; 2(3):232-60. PubMed ID: 21779496
[TBL] [Abstract][Full Text] [Related]
2. A-Raf: A new star of the family of raf kinases.
An S; Yang Y; Ward R; Liu Y; Guo XX; Xu TR
Crit Rev Biochem Mol Biol; 2015; 50(6):520-31. PubMed ID: 26508523
[TBL] [Abstract][Full Text] [Related]
3. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway.
Zhao J; Luo Z
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563547
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
7. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
8. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts.
Galabova-Kovacs G; Kolbus A; Matzen D; Meissl K; Piazzolla D; Rubiolo C; Steinitz K; Baccarini M
Cell Cycle; 2006 Jul; 5(14):1514-8. PubMed ID: 16861903
[TBL] [Abstract][Full Text] [Related]
9. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.
Song Y; Bi Z; Liu Y; Qin F; Wei Y; Wei X
Genes Dis; 2023 Jan; 10(1):76-88. PubMed ID: 37013062
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy.
Huang Y; Zhen Y; Chen Y; Sui S; Zhang L
Biochem Pharmacol; 2023 Nov; 217():115842. PubMed ID: 37802240
[TBL] [Abstract][Full Text] [Related]
11. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo.
O'Neill E; Kolch W
Cell Cycle; 2005 Mar; 4(3):365-7. PubMed ID: 15701972
[TBL] [Abstract][Full Text] [Related]
12. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
13. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.
Avruch J; Khokhlatchev A; Kyriakis JM; Luo Z; Tzivion G; Vavvas D; Zhang XF
Recent Prog Horm Res; 2001; 56():127-55. PubMed ID: 11237210
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation.
Troppmair J; Bruder JT; Munoz H; Lloyd PA; Kyriakis J; Banerjee P; Avruch J; Rapp UR
J Biol Chem; 1994 Mar; 269(9):7030-5. PubMed ID: 8120067
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic B-Raf mutations: crystal clear at last.
Dhillon AS; Kolch W
Cancer Cell; 2004 Apr; 5(4):303-4. PubMed ID: 15093535
[TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
[TBL] [Abstract][Full Text] [Related]
20. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
